Drug interactions
Paclitaxel protein bound + Rosiglitazone
Severity: Minor
Paclitaxel protein bound and Rosiglitazone: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Paclitaxel is metabolized mainly by CYP2C8, and rosiglitazone is a substrate with weak inhibitory potential for this enzyme. A clinically meaningful rise in paclitaxel exposure is not well established.
What this interaction means in plain words
Paclitaxel protein bound and Rosiglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Possible competition for CYP2C8 metabolism; clinical significance unproven.
What to do
No dose change needed. Monitor for paclitaxel toxicity such as neutropenia and neuropathy as usual.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Paclitaxel protein bound and Rosiglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rosiglitazone
- Insulin aspart protamine / insulin aspart + Rosiglitazone Major
- Insulin aspart-insulin aspart protamine + Rosiglitazone Major
- Insulin aspart + Rosiglitazone Major
- Insulin degludec / insulin aspart + Rosiglitazone Major
- Insulin degludec-insulin aspart + Rosiglitazone Major
- Insulin degludec-liraglutide + Rosiglitazone Major
Frequently asked questions
Can I take Paclitaxel protein bound with Rosiglitazone?
MediHelp rates the interaction as minor. Paclitaxel protein bound and Rosiglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Paclitaxel is metabolized mainly by CYP2C8, and rosiglitazone is a substrate with weak inhibitory potential for this enzyme. A clinically meaningful rise in paclitaxel exposure is not well established.
How serious is the interaction between Paclitaxel protein bound and Rosiglitazone?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change needed. Monitor for paclitaxel toxicity such as neutropenia and neuropathy as usual.
What other medicines interact with Rosiglitazone?
MediHelp also lists interactions of Rosiglitazone with, for example, Insulin aspart protamine / insulin aspart, Insulin aspart-insulin aspart protamine, Insulin aspart. The full list is on the Rosiglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
